Replimune Group, Inc. (NASDAQ:REPL) Sees Significant Drop in Short Interest

Replimune Group, Inc. (NASDAQ:REPL) saw a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 5,580,000 shares, a decrease of 16.5% from the November 15th total of 6,680,000 shares. Based on an average daily volume of 828,800 shares, the short-interest ratio is currently 6.7 days.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research note on Friday, November 22nd. Roth Capital raised Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. BMO Capital Markets raised their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 22nd. JPMorgan Chase & Co. lifted their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. Finally, Jefferies Financial Group increased their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $17.29.

Insider Activity

In other news, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at $1,184,560.30. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 8.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its position in shares of Replimune Group by 12.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock worth $5,313,000 after purchasing an additional 52,498 shares during the last quarter. LMR Partners LLP increased its position in Replimune Group by 145.8% in the 3rd quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock worth $904,000 after buying an additional 48,920 shares during the period. Millennium Management LLC lifted its holdings in shares of Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after buying an additional 2,656,173 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in shares of Replimune Group by 282.2% in the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock valued at $650,000 after acquiring an additional 53,313 shares during the period. Finally, Acadian Asset Management LLC grew its stake in shares of Replimune Group by 63.2% in the second quarter. Acadian Asset Management LLC now owns 185,516 shares of the company’s stock worth $1,668,000 after acquiring an additional 71,867 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Stock Up 2.7 %

Shares of Replimune Group stock opened at $12.55 on Friday. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock has a 50 day moving average price of $12.19 and a two-hundred day moving average price of $10.45. The stock has a market capitalization of $858.67 million, a P/E ratio of -4.11 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.07. Equities analysts expect that Replimune Group will post -2.91 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.